Clinical trial
Study of XL999 in Patients With Multiple Myeloma
NCT00304590 · Symphony Evolution, Inc., Industry · Terminated
Key facts
| NCT number | NCT00304590 |
|---|---|
| Title | Study of XL999 in Patients With Multiple Myeloma |
| Official title | A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma |
| Lead sponsor | Symphony Evolution, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | XL999 |
| Enrollment | 4 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Mar 20, 2006 |
| Last update posted | Feb 22, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: